Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

984 - Screening for Lynch syndrome among endometrial cancer patients less than 60 years


08 Oct 2016


Poster Display


ELENA Aguirre


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


E. Aguirre1, M. Mele2, N. Tuset3, A. Velasco4, J. Tarragona5, M. Sampayo6, S. Serrano2, F. Riu7, M. Rodriguez-Balada7, X. Matias-Guiu5, E. Garcia8, E. Ortega3, J. BalmaÑa9

Author affiliations

  • 1 Oncology, HOSPITAL QUIRON, 50012 - Zaragoza/ES
  • 2 Oncology, University Hospital St. Joan de Reus, Reus/ES
  • 3 Oncology, Hospital Universitario Arnau Vilanova de Lleida, Lerida/ES
  • 4 Molecular Biology, Hospital Universitario Arnau Vilanova de Lleida, Lerida/ES
  • 5 Pathology, Hospital Universitario Arnau Vilanova de Lleida, Lerida/ES
  • 7 Pathology, University Hospital St. Joan de Reus, Reus/ES
  • 8 Radiotherapy, Hospital Universitario Arnau Vilanova de Lleida, Lerida/ES
  • 9 Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona/ES


Abstract 984


Lynch Syndrome (LS) is an autosomal dominant disorder caused by germline mutations in any of the mismatch repair genes (MMR): MLH1, MSH2, MSH6 or PMS2. Although colorectal cancer is the most common tumour associated to the syndrome, the risk of endometrial cancer may be higher in some mutation carriers and be diagnosed at an earlier age. Therefore, identifying LS among endometrial cancer patients is crucial to identify LS and also help preventing colorectal cancer as a potential secondary malignancy.


Patients with endometrial cancer diagnosed less than 60 years of age were prospectively enrolled and their personal and family history was collected. All cases were evaluated for microsatellite instability (MSI), MMR protein expression by immunohistochemistry (IHC) and hypermethylation of the MLH1 promoter (if lack of expression of MLH1 was found). Patients with MSI and/or abnormal immunohistochemical staining were tested for germline mutations by DNA sequencing and large rearrangements analysis, once hypermethylation of the MLH1 promoter was ruled out.


76 endometrial cancer patients were included, median age was 53 years (range 33-60 years). 27 patients (35%) had molecular findings suggestive of Lynch syndrome and were referred for germline genetic testing. 14 patients (18%) with LS due to a germline mutation in the MMR genes were detected: two patients with a MLH1 mutation, six patients with a MSH2 mutation and six patients with a MSH6 mutation. Despite mutation carriers met classical clinical criteria more frequently than no carriers (p = 0.001), 29% of mutation carriers did not fulfil them. IHC combined with MLH1 promoter hypermethylation analysis was the most efficient method to select patients for genetic testing with sensitivity of 100%, specificity of 81% and positive predictive value of 54%.


Almost one out five patients with endometrial cancer less than 60 years is carrier of a germline mutation in LS. This justifies referring these patients for genetic counselling and testing. The best screening method to select patients is the combination of IHC with MLH1 promoter hypermethylation for those cases with lack of expression of MLH1.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings